How genomic characteristics indicating homologous recombination deficiency (HRD) are measured, integrated, and distilled varies across assays, which can create uncertainty around treatment options and enrollment into clinical trials. This also makes the path of follow-on companion diagnostics challenging because perfect agreement between imprecise measurements is unlikely.
This poster from LGC SeraCare presents data on the characterization and implementation of a set of reference materials, composed of HRD negative, borderline, and positive tumor/normal matched cell lines, for the standardization of HRD assessment.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences